Alvotech

Overview
News
Biosimilars?
Product stageSegments
Growth
?
Pure Play Biosimilars Developers
?

Alvotech is a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Founded by Robert Wessman, Alvotech aims to improve lives by expanding access to affordable biologic medicines. The company employs a vertically integrated approach, controlling the entire process from cell line development through fill and finish manufacturing. This gives Alvotech the control, scale and speed needed to achieve its mission.

Alvotech's lead product is Simlandi (adalimumab-ryvk), a biosimilar to Humira. In February 2024, Simlandi became the first high-concentration, citrate-free biosimilar to Humira to receive FDA approval with interchangeability designation in the US. This allows pharmacies to substitute Simlandi for Humira without consulting the prescriber. Alvotech's US commercial partner Teva Pharmaceutical is responsible for marketing and selling Simlandi.

The company has a pipeline of eight disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. In October 2023, Alvotech entered an exclusive licensing agreement with Kashiv BioSciences for the development and commercialization of ADL018, a proposed biosimilar to Xolair (omalizumab), which is in clinical development.

Alvotech became a publicly traded company in June 2022, listing on the Nasdaq stock market under the ticker "ALVO". This represented the largest debut on a US stock exchange by an Icelandic company. Alvotech's shares also trade on the Nasdaq First North Growth Market in Iceland.

Key customers and partnerships

Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets worldwide. Key partners include Teva Pharmaceuticals (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea).

Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
Saemundargata 15-19 Reykjavík ISL
Founded year:
2013
Employees:
501-1,000
IPO status:
Public
Total funding:
USD 1.7 bn
Last Funding:
USD 965.0 mn (Post IPO Debt; Jun 2024)
Last valuation:
USD 1.5 bn (Oct 2020)
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.